Nkarta to Participate at Upcoming Investor Conference

Rhea-AI Summary

Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company focused on engineered natural killer cell therapies for cancer, will participate in the 21st Annual Needham Virtual Healthcare Conference on April 12, 2022, at 4:30 p.m. ET. A webcast of the presentation will be available in the Investors section of Nkarta’s website and can be accessed after the live event for approximately four weeks. Nkarta specializes in developing off-the-shelf NK cell therapies designed for outpatient treatments, leveraging advanced cell engineering and cryopreservation technologies.

News Market Reaction – NKTX

-6.73%

-6.73% Session move

In the trading session that priced this news, NKTX declined 6.73%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SOUTH SAN FRANCISCO, Calif., April 08, 2022 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced its participation at an upcoming investor conference:

21st Annual Needham Virtual Healthcare Conference
April 12, 2022
4:30 p.m. ET – presentation

A simultaneous webcast of the event will be available on the Investors section of Nkarta’s website, www.nkartatx.com, and a replay will be archived on the website for approximately four weeks.

About Nkarta
Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies for cancer patients. By combining its cell expansion and cryopreservation platform with proprietary cell engineering technologies and CRISPR-based genome engineering capabilities, Nkarta is building a pipeline of future cell therapies engineered for deep anti-tumor activity and intended for broad access in the outpatient treatment setting. For more information, please visit the company’s website at www.nkartatx.com.

Nkarta Media/Investor Contact:
Greg Mann
Nkarta, Inc.
gmann@nkartatx.com

 

FAQ

What is Nkarta's participation in the 21st Annual Needham Virtual Healthcare Conference?

Nkarta, Inc. will present at the 21st Annual Needham Virtual Healthcare Conference on April 12, 2022, at 4:30 p.m. ET.

Where can I watch Nkarta's presentation from the healthcare conference?

You can watch Nkarta's presentation via a live webcast available on the Investors section of Nkarta’s website.

How long will the replay of Nkarta's conference presentation be available?

The replay of Nkarta's conference presentation will be archived for approximately four weeks.

What is the focus of Nkarta, Inc.?

Nkarta, Inc. focuses on developing engineered natural killer cell therapies aimed at treating cancer patients.

What technologies does Nkarta use in their NK cell therapies?

Nkarta utilizes cell expansion, cryopreservation, and CRISPR-based genome engineering technologies in their NK cell therapies.